What happened with IONS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Ionis Pharmaceuticals makes medicines designed to change gene activity by targeting RNA. Pharmaceutical partners pay to license its medicines and fund research, then make further payments when development, approval or sales goals are met. Once partnered medicines reach the market, Ionis receives a share of their sales as royalties. Collaboration payments and royalties together account for most revenue, with research and development collaborations the largest source.
Biogen sells SPINRAZA worldwide, and this medicine supplies most of Ionis’s royalty revenue. Ionis has sold part of that royalty stream to Royalty Pharma, so it does not retain all the cash. AstraZeneca jointly markets WAINUA with Ionis in the United States and holds exclusive commercialization rights elsewhere. Ionis also sells TRYNGOLZA and DAWNZERA independently in the United States; TRYNGOLZA accounts for most of its own product sales, primarily through one unnamed customer.
The business depends heavily on partners funding development and selling licensed medicines. Biogen and Ono each supply a substantial share of revenue, with Ono’s contribution largely tied to an upfront payment for licensing the investigational medicine sapablursen. AstraZeneca is another important revenue source. Product income also depends on payer coverage and agreed prices. Regulatory conditions can limit commercialization: WAYLIVRA’s European label requires regular blood monitoring, and its conditional approval requires a post-authorization safety study.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ionis also relies on partners missing from this list: Ono supplied 30% of its 2025 revenue through the sapablursen agreement, while Roche develops several licensed Ionis medicines.
Biogen pays Ionis for licensed medicines and neurology research, supplying 31% of Ionis’s 2025 revenue. Watch Biogen’s SPINRAZA sales: Ionis receives 11%–15% of net sales as royalties, while Biogen funds development and commercialization.
Alnylam’s ONPATTRO and AMVUTTRA compete for ATTR amyloidosis patients with Ionis’s TTR-targeting medicines. Alnylam’s sales of these treatments are worth watching alongside WAINUA sales, from which Ionis earns royalties.
Arrowhead’s REDEMPLO competes directly with Ionis’s TRYNGOLZA for familial chylomicronemia syndrome patients. Their patent dispute over plozasiran also matters: Arrowhead says Ionis’s claim could affect REDEMPLO commercialization.
AstraZeneca licenses Ionis programs and shares WAINUA development and commercialization, paying Ionis royalties, milestones and development-cost funding. U.S. approval of WAINUA for ATTR cardiomyopathy could trigger a $200 million payment to Ionis.
Novartis funds development of licensed Ionis medicine pelacarsen for patients with elevated Lp(a) and cardiovascular disease; approval and sales would bring Ionis milestone payments and royalties. FDA acceptance of its new-drug application could trigger the next $50 million payment.
BridgeBio Pharma’s oral Attruby already serves ATTR cardiomyopathy patients in the market Ionis aims to enter with WAINUA. Its $362.4 million in 2025 U.S. net product revenue gives investors a concrete sales benchmark for a competing treatment.
BioCryst Pharmaceuticals Inc’s once-daily oral ORLADEYO competes with Ionis’s DAWNZERA to prevent hereditary angioedema attacks. Watch ORLADEYO sales to patients aged 12 and older, the patient group covered by DAWNZERA’s approval.
Intellia Therapeutics, Inc’s Phase 3 gene-editing programs could compete for the HAE and ATTR patients served by Ionis’s DAWNZERA and WAINUA. Watch lonvo-z’s development and approval progress: Intellia planned a U.S. launch in the first half of 2027, conditional on those steps.
Pfizer’s Vyndaqel and Vyndamax compete with Ionis’s TEGSEDI and WAINUA in ATTR amyloidosis, including the cardiomyopathy market WAINUA aims to enter. Pfizer’s oral treatments are already approved for ATTR cardiomyopathy in the U.S., EU and other markets.
Takeda’s Takhzyro and Cinryze compete with Ionis’s DAWNZERA to prevent hereditary angioedema attacks. Takhzyro is injected under the skin and Cinryze is infused into a vein; both cover the patients aged 12 and older eligible for DAWNZERA.
GSK funds development and commercialization of licensed Ionis hepatitis B medicine bepirovirsen, with progress and eventual sales bringing Ionis milestone payments and potential royalties. Acceptance of a new-drug application or foreign equivalent for review in a major country could trigger the next $15 million payment.
Ultragenyx Pharmaceutical Inc.’s Phase 3 apazunersen competes with Ionis’s obudanersen in development for Angelman syndrome, with both using antisense medicines. Apazunersen’s trial progress is the direct comparison to watch for this Ionis program.
Wave Life Sciences Ltd. competes with Ionis in RNA medicines, including programs for Huntington’s disease. Watch Wave’s Huntington’s development alongside tominersen, which Roche licenses from Ionis and develops at its own cost.
Pharvaris N.V.’s Phase 3 oral deucrictibant prevention program could compete with Ionis’s DAWNZERA for hereditary angioedema patients. Watch the extended-release tablet’s prevention study, rather than the separate immediate-release capsule program for treating attacks as they occur.
ADARx Pharmaceuticals’ Phase 3 ADX-324 could compete with Ionis’s DAWNZERA to prevent hereditary angioedema attacks. Watch trials of this under-the-skin treatment, which uses RNA silencing to reduce prekallikrein.
PTC Therapeutics sells licensed Ionis medicines TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries, paying Ionis royalties in the mid-20% range of net sales. Sales of those two medicines in that territory—not their broader approvals—drive this income for Ionis.
BridgeBio Pharma, Inc. earningsBBIO
BridgeBio's report will show how strongly its oral ATTR cardiomyopathy drug Attruby is selling in the market Ionis hopes to enter with WAINUA.
Watch Attruby product sales. Strong sales would show that this market has commercial demand and that WAINUA would face a competitor with an established foothold. Weak sales would show limited traction for Attruby, but would not prove that patients will also reject WAINUA. The question for Ionis is whether it can build sales in this competitive market.
Biogen Inc. earningsBIIB
Biogen's report will show how SPINRAZA is selling; Ionis earns royalties on the drug's net sales, so those sales shape this revenue stream.
Watch SPINRAZA sales alongside the royalties Ionis earns from the drug. Steady or rising sales support the royalty stream, which is calculated at 11% to 15% of net sales; falling sales put that income under pressure. This shows how Biogen's sales flow through to Ionis's commercial revenue.
AstraZeneca PLC earningsAZN
AstraZeneca's report can show how the WAINUA partnership is progressing and what that means for Ionis's development-cost funding, royalties, and potential milestone payments.
Watch AstraZeneca's disclosures on WAINUA development and commercialization, and distinguish partnership progress from the R&D revenue and royalties Ionis recognizes. Progress may support development-cost funding or future revenue; limited progress offers less support for those income paths. The point is whether this partnership is advancing Ionis's revenue opportunities, not whether AstraZeneca's overall results are strong.
BioCryst Pharmaceuticals Inc earningsBCRX
BioCryst's report will show how its oral drug ORLADEYO sells to patients in the same age group covered by Ionis's DAWNZERA.
Watch ORLADEYO sales. Rising sales would show demand among patients aged 12 and older for an oral preventive treatment, strengthening the competition DAWNZERA faces. Weak sales would show limited traction in this group, but would not establish that DAWNZERA sales will rise. The report helps gauge how much pressure oral competition puts on DAWNZERA's market.
Ionis Pharmaceuticals, Inc. earningsThis company
This report shows whether Ionis can grow medicine sales and royalties from partner drugs, rather than relying mainly on collaboration payments to support drug development.
Read product sales and royalties alongside collaboration and R&D revenue, R&D spending, and the net loss. Rising sales and royalties, with less reliance on collaboration revenue and a narrowing loss, would show that medicines such as TRYNGOLZA and partner medicines are building a broader commercial base. If commercial revenue remains weak and collaboration payments do most of the work, even higher total revenue would not show that Ionis has built a market-driven base to support its development costs.
Arrowhead Research Corporation earningsARWR
Arrowhead's report will show how REDEMPLO is selling in the familial chylomicronemia syndrome market it shares with Ionis's TRYNGOLZA.
Watch REDEMPLO sales. Strong sales would show that this direct competitor is attracting patients and payers, leaving TRYNGOLZA to contend with stronger commercial competition. Weak sales would show limited commercial traction for REDEMPLO, but would not mean patients will switch to TRYNGOLZA. The question is whether Ionis can build its own sales in the same patient market.
